Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, UroGen Pharma Ltd (NASDAQ: URGN) closed at $12.48 down -1.73% from its previous closing price of $12.70. In other words, the price has decreased by -$1.73 from its previous closing price. On the day, 0.84 million shares were traded. URGN stock price reached its highest trading level at $12.785 during the session, while it also had its lowest trading level at $12.22.
Ratios:
For a deeper understanding of UroGen Pharma Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.93 and its Current Ratio is at 8.15. In the meantime, Its Debt-to-Equity ratio is 3.27 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on August 22, 2024, initiated with a Buy rating and assigned the stock a target price of $40.
On February 08, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $35 to $10.
On April 27, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $20.Berenberg initiated its Buy rating on April 27, 2022, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 09 ’24 when Schoenberg Mark sold 859 shares for $13.08 per share. The transaction valued at 11,236 led to the insider holds 145,091 shares of the business.
Smith Jason Drew sold 1,521 shares of URGN for $19,895 on Sep 09 ’24. The General Counsel now owns 25,226 shares after completing the transaction at $13.08 per share. On Sep 09 ’24, another insider, Schoenberg Mark, who serves as the Officer of the company, bought 859 shares for $13.23 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 525583936 and an Enterprise Value of 383539584. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.18 while its Price-to-Book (P/B) ratio in mrq is 16.95. Its current Enterprise Value per Revenue stands at 4.512 whereas that against EBITDA is -4.878.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $20.70, while it has fallen to a 52-week low of $10.60. The 50-Day Moving Average of the stock is -13.34%, while the 200-Day Moving Average is calculated to be -17.43%.
Shares Statistics:
For the past three months, URGN has traded an average of 480.90K shares per day and 641500 over the past ten days. A total of 42.11M shares are outstanding, with a floating share count of 38.20M. Insiders hold about 9.30% of the company’s shares, while institutions hold 97.78% stake in the company. Shares short for URGN as of 1726185600 were 6369328 with a Short Ratio of 13.24, compared to 1723680000 on 6486557. Therefore, it implies a Short% of Shares Outstanding of 6369328 and a Short% of Float of 15.479999999999999.
